Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases

Medicine and Dentistry

• Tumor Necrosis Factor 100%
• Health Care Cost 60%
• Therapeutic Drug Monitoring 60%
• Drug Antibody 60%
• Combination Therapy 40%
• Prospective Study 40%
• Patient with Inflammatory Bowel Disease 40%
• TNF Inhibitor 40%
• Trough Level 40%
• Health 40%
• Inpatient 40%
• Measurement 20%
• Biological Product 20%
• Spontaneous Remission 20%
• Therapeutic Procedure 20%
• Monitoring 20%
• Patient 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Therapeutic Drug Monitoring 60%
• Drug Antibody 60%
• Tumor Necrosis Factor Inhibitor 40%
• Trough Level 40%
• Biological Product 20%
• Remission 20%
• Inflammatory Bowel Disease 20%